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Muscle atrophy through thick but not thin
D
uring desperate times, the body 
cannibalizes itself, breaking 
down skeletal muscle proteins to 
liberate amino acids. Shenhav Cohen, 
Alfred Goldberg, and colleagues show 
that a key enzyme in the process is picky, 
driving the destruction of the thick fi  la-
ments in muscle and bypassing the thin 
fi  laments (1). Though we think of muscle 
atrophy as chaotic, it is surprisingly orderly, 
the work suggests.
We depend on skeletal muscles 
because they can produce movement, but 
they serve another purpose too. “Skeletal 
muscle is a protein reservoir that can be 
mobilized in times of need,” says Goldberg. 
Muscles bulk down during fasting,  during 
the severe wasting known as cachexia that 
often affl   icts cancer and AIDS patients, 
and during other metabolic emergencies. 
Disuse, such as in a bedridden patient or a 
skier with a broken leg or nerve injury, also 
spurs muscles to shrink, as they adjust their 
size to the lower workload (2).
The structural core of a muscle 
cell is the myofi  bril, which is composed 
of myosin-containing thick fi  laments and 
actin-containing thin fi  laments. These inter-
locking strands slide past one another during 
contraction. Researchers have begun to tease 
apart the mechanism that disassembles this 
intricate structure during atrophy sparked by 
fasting and illness. The Foxo transcription 
factors (3) and NF-B lead off, turning on 
a set of atrophy-related genes that includes 
MuRF1 and atrogin-1. Both of these genes 
encode ubiquitin ligases that affi  x ubiquitin 
to a target protein so that it can be minced in 
the proteasome, the cell’s recycling center. 
Still unclear is when and how the ubiquity-
lation enzymes get into the act. Some earlier 
studies (4, 5) suggested that other proteases 
such as caspases and calpains must fi  rst at-
tack the myofi  bril components, liberating 
them for ubiquitylation and destruction. 
But it’s also possible that ubiquitylating 
enzymes act directly on the thick and thin 
fi  laments within a myofi  bril.
Cohen et al. addressed the issue by 
investigating mice in which the normal 
MuRF1 gene had been swapped for either a 
labeled but functional version or a dud ver-
sion that lacked the RING-fi  nger domain 
crucial for ubiquitylation. Snipping the 
animals’ sciatic nerve on one side triggered 
muscle atrophy. In mice with the defec-
tive MuRF1, less muscle broke down. The 
weight of the gastrocnemius muscle de-
clined by only 22%, versus 36% in animals 
with functional MuRF1. Less ubiquitylation 
also occurred when MuRF1 was faulty.
The researchers found that MuRF1 
works on the intact myofi  bril. It targeted 
four components of the thick fi  lament: the 
two myosin light chains, myosin-binding 
protein C, and the myosin heavy chain. 
However, these proteins didn’t break down 
simultaneously. Demoli-
tion of the light chains and 
myosin-binding protein C 
was well underway 10 days 
after the team cut the sci-
atic nerve. But at this time 
the myosin heavy chain 
remained untouched. Four 
days later, it had begun to 
break down. Why the delay? The research-
ers hypothesize that removal of the other 
thick fi  lament components allows MuRF1 
access to the myosin heavy chain.
MuRF1 doesn’t exert the same power 
over components of the thin fi  lament, 
including actin and tropomyosin. They 
began to come apart even when MuRF1 
was absent. That distinction suggests that 
a different process—probably involving 
another ubiquitin-wielding protein—
dismantles the thin fi  lament.
“Up to now, people thought the 
muscle just gets smaller” during atrophy, 
Goldberg says. Instead, these fi  ndings paint 
a picture of a well-regulated process of deg-
radation and disassembly. This mechanism 
“allows the muscle to still be a muscle and 
function,” Goldberg says. “Atrophy doesn’t 
just destroy muscle cells, like apoptosis.” 
The results indicate that MuRF1 doesn’t 
have to wait for caspases or calpains to 
“pre-digest” the myofi  bril components. The 
work also bears on the practical question of 
whether atrophy can be halted or reversed 
with drugs. “It argues against MuRF1 in-
hibitors” for this purpose, 
Goldberg says, because 
the enzyme is respon-
sible for degrading only 
some muscle components, 
whereas others fall victim 
to other ubiquitin ligases 
and autophagy. Inhibi-
tors that work upstream to 
block signals that activate ubiquitin ligases 
and initiate autophagy are a better bet.
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Shenhav Cohen (left), Alfred Goldberg, and colleagues determined which muscle proteins 
the ubiquitylating enzyme MuRF1 attacks. Activation of the transcription factor Foxo3 (red) 
drives expression of MuRF1, which then homes in on thick ﬁ  laments in a myoﬁ  bril.
“Skeletal muscle 
is a protein 
reservoir that can 
be mobilized in 
times of need.”
Ubiquitylating enzyme MuRF1 targets thick fibers in muscle.
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